New Market Research Report: Lithuania Pharmaceuticals & Healthcare Report Q1 2016

Lithuania's pharmaceutical and healthcare market represents a modest prospect for investment from multinational firms. Increasing demand due to a rising burden of chronic disease will translate to an increase in sales; however, fiscal policies and the small size of the market will limit revenue earning opportunities.

Headline Expenditure Projections

Pharmaceuticals: EUR601mn (USD806mn) in 2014 to EUR616mn (USD677mn) in 2015; +2.4% in local currency terms and -16.0% in US dollar terms. Forecast revised downwards from Q215.

Healthcare: EUR2.14bn (USD2.87bn) in 2014 to EUR2.14bn (USD2.36bn) in 2015; +0.1% in local currency terms and -17.8% in US dollar terms. Forecast revised downwards from Q215.

Risk/Reward Index

Lithuania has an RRI score of 49.1 out of 100, making it the 12th most attractive pharmaceutical market in Central and Eastern Europe. Lithuania scores below the regional average score of 49.6 in Q116. Lithuania scores 13.6 for Industry Rewards, below the regional average (16.8), with the country's limited size holding back its score. Lithuania's overall Reward score of 27.7 is below the regional average (29.9), highlighting the limited growth outlook for pharmaceuticals and the small overall size of the Lithuanian market.

Full Report Details at
- http://www.fastmr.com/prod/1119035_lithuania_pharmaceuticals.aspx?afid=301

Latest Updates

In October 2015, Lithuania's members of parliament approved a 2016 draft budget for the Compulsory Health Insurance Fund.

In October 2015, the European Commission's vice president advised Lithuania to improve the accessibility of electronic health services.

Bioresus announced plans to build a factory in Alytus for the production of heparin, with production to start in 2017.

BMI Economic View

Lithuania will record a slightly larger budget deficit over our short-term outlook on the back of increase expenditures and stagnant revenue growth. However, much like its Baltic neighbours, the deficit will be small and manageable, financed through a small increase in public debt.

BMI Political View

Tensions with Russia will continue however, Russia's increasing involvement in the Middle East and Lithuania's membership of NATO mean we do not expect Russia to launch any kind of military attack in 2016. Nonetheless, it is likely that displays of aggression will continue in the form of new military bases being constructed close to the Lithuanian border and troop movements designed to intimidate.

The Lithuania Pharmaceuticals & Healthcare Report features BMI Research's forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

About Fast Market Research

Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156 (1.413.485.7001 Int'l)

You may also be interested in these related reports:

- France Pharmaceuticals & Healthcare Report Q1 2016
- Saudi Arabia Pharmaceuticals & Healthcare Report Q1 2016
- Kenya Pharmaceuticals & Healthcare Report Q1 2016
- Ukraine Pharmaceuticals & Healthcare Report Q1 2016
- Thailand Pharmaceuticals & Healthcare Report Q1 2016